NOVELIX PHARMACEUTICALS LIMITE Share Price
₹ 77.97
-₹0.63 (-0.8%)
1D
Last updated 03 Jul, 2026, 15:24 IST
NOVELIX PHARMACEUTICALS LIMITE Share Price Today
As of 5 Jul 2026, NOVELIX PHARMACEUTICALS LIMITE share price is ₹77.97. The stock opened at ₹78.60, compared to its previous close of ₹78.60. During today's trading session, NOVELIX PHARMACEUTICALS LIMITE share price moved in the range of ₹74.67 to ₹78.60, with an average price of ₹76.63 for the day. Looking at its last 52-week, the stock has touched a low of ₹37.71 and a high of ₹92.00.
₹74.67
0.80% down today
₹78.60
1D LOW1D HIGH
Latest Earning
Op Profit TrendUp by 45.87% YoYLatest Earning
Net Profit TrendUp by 46.01% YoYLatest Earning
Revenue TrendDown by 8.45% QoQStock Performance
OutperformingBeat Nifty by 46.28 % in last 1 monthShareholding Pattern
PromoterPromoter increased stake by 2.29%NOVELIX PHARMACEUTICALS LIMITE Returns Calculator
If you would've invested
₹
₹1,000₹1Cr
Historical Returns
1 Year
₹9,70,259+₹4,70,259 (+94.05%)
3 Year
₹39,18,090+₹34,18,090 (+683.62%)
5 Year
₹49,03,774+₹44,03,774 (+880.75%)
Market Overview
Fundamentals
Financials
Technicals
About
Events
FAQs
Open
₹78.60
High
₹78.60
Low
₹74.67
Prev. close
₹78.60
Volume
12,519
Average traded price
₹76.04
Last traded time
03:24:21 03 Jul
Last traded quantity
2,365
₹74.08₹81.86
Circuit LowCircuit High
₹37.71₹92.00
52-Week Low52-Week High
Circuit
LH
₹74.08
₹81.86
52-week
LH
₹37.71
₹92.00
NOVELIX PHARMACEUTICALS LIMITE Shareholder Returns
1 day
-0.80%
1 week
-2.54%
1 month
+43.43%
1 year
+96.45%
3 years
+763.46%
5 years
+911.28%
NOVELIX PHARMACEUTICALS LIMITE Share Price History
Day
Open / Close
Change %
03 Jul 26
₹78.60 / ₹77.97
-0.80%
02 Jul 26
₹80.00 / ₹78.60
-0.51%
01 Jul 26
₹79.00 / ₹79.00
+2.80%
30 Jun 26
₹78.70 / ₹76.85
-1.30%
29 Jun 26
₹76.00 / ₹77.86
-2.68%
25 Jun 26
₹81.00 / ₹80.00
+3.55%
24 Jun 26
₹83.00 / ₹77.26
-3.68%
23 Jun 26
₹79.61 / ₹80.21
+0.75%
Show more
Mkt Cap Cr
58.64
P/E
-27.00
P/B
3.24
ROE
-30.18%
D/E
0.09
ROCE
-32.45%
Div. Yield
0.00%
EPS(TTM)
1.21
Turnover
2.60
EV/EBITDA
-23.57
Net Margin
0.00%
Op. Margin
0.00%
ROA
-30.18%
Quick Ratio
0.00
Curr. Ratio
2.14
Mkt Cap Cr
58.64
P/E
-27.00
P/B
3.24
ROE
-30.18%
D/E
0.09
ROCE
-32.45%
Div. Yield
0.00%
EPS(TTM)
1.21
Turnover
2.60
EV/EBITDA
-23.57
Net Margin
0.00%
Op. Margin
0.00%
ROA
-30.18%
Quick Ratio
0.00
Curr. Ratio
2.14
Based on fundamentals, this stock's
5/5
Performance
Excellent
Novelix Pharma. outperforming all market indices
1/5
Valuation
Overvalued
Novelix Pharma. appears overvalued compared to its peers
3/5
Earnings
Neutral
Novelix Pharma. earnings growth is positive
Peer Comparison
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
NOVELIX PHARMACEUTICALS LIMITE Financials
Full statement
Income Statement · Consolidated
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Revenue | ₹8.61 | ₹9.24 | ₹10.24 | ₹9.89 |
| Other Income | ₹0.55 | ₹0.34 | ₹0.60 | ₹0.95 |
| Total Revenue | ₹9.16 | ₹9.59 | ₹10.85 | ₹10.84 |
| Total Expenses | ₹11.23 | ₹10.35 | ₹11.06 | ₹10.96 |
| Profit Before Tax | -₹2.03 | -₹3.75 | -₹0.21 | -₹0.12 |
| Tax | -₹0.01 | ₹0.01 | ₹0.04 | ₹0.02 |
| Profit After Tax | -₹2.03 | -₹3.76 | -₹0.26 | -₹0.15 |
| EPS - Basic | -₹2.22 | -₹4.62 | -₹0.35 | -₹0.30 |
| EPS - Diluted | -₹2.22 | -₹4.62 | -₹0.35 | -₹0.30 |
Cash Flow · Consolidated
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Profit before tax | -₹2.12 | -₹3.73 | -₹0.21 | -₹0.12 |
| Income before WC changes | ₹0.01 | -₹3.80 | -₹0.41 | -₹0.16 |
| Change in Assets | ₹2.21 | ₹5.02 | ₹0.25 | -₹0.31 |
| Change in Liabilities | -₹1.11 | ₹0.39 | ₹0.90 | -₹0.06 |
| Change in WC | ₹1.09 | ₹5.42 | ₹1.15 | -₹0.37 |
| Cash flow from Operations | ₹1.59 | ₹1.59 | ₹0.63 | -₹0.53 |
| Cash flow from Investing | -₹0.76 | ₹0.14 | ₹0.45 | ₹0.43 |
| Cash flow from Financing | ₹0.00 | -₹0.77 | -₹0.16 | -₹0.05 |
| Total Cash Flow | ₹0.83 | ₹0.96 | ₹0.92 | -₹0.15 |
| Cash (Start of the year) | ₹2.06 | ₹1.12 | ₹0.20 | ₹0.35 |
| Cash (End of the year) | ₹2.89 | ₹2.08 | ₹1.12 | ₹0.20 |
Balance Sheet · Consolidated
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Non-Current Assets | ₹2.81 | ₹2.24 | ₹2.33 | ₹2.62 |
| Current Assets | ₹5.93 | ₹7.33 | ₹11.39 | ₹10.72 |
| Total Assets | ₹8.74 | ₹9.57 | ₹13.72 | ₹13.34 |
| Current Liabilities | ₹0.93 | ₹2.18 | ₹1.81 | ₹0.99 |
| Net Current Asset | ₹5.00 | ₹5.16 | ₹9.58 | ₹9.73 |
| Non-Current Liabilities | ₹0.13 | ₹0.03 | ₹0.79 | ₹0.93 |
| Equity Capital | ₹7.68 | ₹7.37 | ₹11.13 | ₹11.42 |
| Total Equity & Liabilities | ₹8.74 | ₹9.57 | ₹13.72 | ₹13.34 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹30.72 | ₹4.22 | ₹1.40 | ₹0.84 |
| Other Income | ₹0.02 | ₹0.31 | ₹0.52 | ₹0.55 |
| Total Revenue | ₹30.73 | ₹4.53 | ₹1.92 | ₹1.39 |
| Total Expenses | ₹30.61 | ₹4.51 | ₹1.98 | ₹2.96 |
| Profit Before Tax | ₹0.12 | ₹0.02 | -₹0.06 | -₹1.57 |
| Tax | ₹0.04 | ₹0.01 | ₹0.00 | -₹0.01 |
| Profit After Tax | ₹0.08 | ₹0.01 | -₹0.06 | -₹1.56 |
| EPS - Basic | ₹0.09 | ₹0.01 | -₹0.07 | -₹1.93 |
| EPS - Diluted | ₹0.09 | ₹0.01 | -₹0.07 | -₹1.93 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹0.12 | ₹0.02 | -₹0.06 | -₹1.57 |
| Income before WC changes | ₹0.15 | -₹0.25 | -₹0.52 | -₹0.53 |
| Change in Assets | -₹22.24 | -₹0.04 | -₹1.94 | ₹1.14 |
| Change in Liabilities | ₹8.41 | -₹0.05 | ₹0.05 | -₹0.02 |
| Change in WC | -₹13.83 | -₹0.10 | -₹1.89 | ₹1.12 |
| Cash flow from Operations | -₹13.68 | -₹0.34 | -₹2.41 | ₹0.59 |
| Cash flow from Investing | ₹2.93 | ₹0.19 | ₹0.08 | ₹0.28 |
| Cash flow from Financing | ₹11.32 | ₹0.00 | ₹0.00 | ₹0.00 |
| Total Cash Flow | ₹0.56 | -₹0.16 | -₹2.33 | ₹0.87 |
| Cash (Start of the year) | ₹0.12 | ₹0.27 | ₹2.60 | ₹1.74 |
| Cash (End of the year) | ₹0.68 | ₹0.12 | ₹0.27 | ₹2.60 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹0.27 | ₹3.24 | ₹3.01 | ₹2.62 |
| Current Assets | ₹26.93 | ₹4.13 | ₹4.24 | ₹4.63 |
| Total Assets | ₹27.21 | ₹7.36 | ₹7.26 | ₹7.25 |
| Current Liabilities | ₹9.67 | ₹0.01 | ₹0.06 | ₹0.01 |
| Net Current Asset | ₹17.27 | ₹4.12 | ₹4.18 | ₹4.62 |
| Non-Current Liabilities | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
| Equity Capital | ₹17.54 | ₹7.35 | ₹7.20 | ₹7.24 |
| Total Equity & Liabilities | ₹27.21 | ₹7.36 | ₹7.26 | ₹7.25 |
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 0
Buy orders: 0%
Sell orders: 0%
30 levels of bid & ask depth
Supply & Demand Zones
Bearish
1
Neutral
5
Bullish
2
Slightly Bullish
by SEBI experts available for this stock
Earn more using advisory
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
57.96
Neutral
ATR (14)
5.35
Neutral
STOCH(9,6)
50.04
Neutral
STOCH RSI (14)
2.28
Bullish
ADX(9)
17.47
Bullish
UO(9)
45.26
Neutral
ROC(12)
-12.2
Bearish
WillR(14)
-70.26
Neutral
Period
Simple value
Exponential vaue
5D
78.06
78.33
10D
78.32
78.25
20D
78.55
75.61
50D
64.24
68.19
100D
60.89
63.52
About NOVELIX PHARMACEUTICALS LIMITE
ISIN
INE314I01036
Sector Market Cap
₹ 58.64 Cr
Novelix Pharmaceuticals Ltd, formerly Trimurthi Limited, is an India-based company, which is engaged in the business of trading pharmaceuticals and related products and is in the business of trading shares and securities. The Company's segments include Pharma Business, Investment is Shares, Trading in shares, Foods, and Finance.
NOVELIX PHARMACEUTICALS LIMITE Financial Highlights
- Revenue: NOVELIX PHARMACEUTICALS LIMITE reported revenue of ₹9.16 crore in FY22 vs ₹9.58 crore in FY21. It showed a decrease of 4.38% on a yearly basis.
- Operating Profit: NOVELIX PHARMACEUTICALS LIMITE reported an operating loss of ₹2.03 crore in FY22 vs ₹3.75 crore in FY21. It showed an increase of 45.87% on a year-on-year basis.
- Net Profit: NOVELIX PHARMACEUTICALS LIMITE reported a net loss of ₹2.03 crore in FY22 vs ₹3.76 crore in FY21. It showed an increase of 46.01% on a yearly basis.
NOVELIX PHARMACEUTICALS LIMITE Quarterly Result Highlights
- NOVELIX PHARMACEUTICALS LIMITE reported revenue of ₹1.30 crore in Sep 2022, compared with ₹1.42 crore in Jun 2022, representing a decrease of 8.45% on a quarter-on-quarter (QoQ) basis.
- NOVELIX PHARMACEUTICALS LIMITE reported an operating loss of ₹0.15 crore in Sep 2022, compared with ₹0.09 crore in Jun 2022, representing a decrease of 66.67% on a quarter-on-quarter (QoQ) basis.
- NOVELIX PHARMACEUTICALS LIMITE reported a loss of ₹0.15 crore in Sep 2022, compared with ₹0.09 crore in Jun 2022, reflecting a decrease of 66.67% on a QoQ basis.
- The earnings per share (EPS) of NOVELIX PHARMACEUTICALS LIMITE stood at ₹2.22 during Sep 2022.
Promoters
50.57%
FII
0.00%
Other DII
0.00%
Retail and other
49.43%
Mutual funds
0.00%
Foreign institutions - FII
Compare against other stocks
NOVELIX PHARMACEUTICALS LIMITE
Trading
Add Stock
Add Another
Similar Stocks
Sun Pharmaceutical Industries
₹1904.65
+33.10 (1.77%)
Divis Laboratories
₹6759.55
+85.35 (1.28%)
Torrent Pharmaceuticals
₹4762.70
+100.10 (2.15%)
Cipla
₹1458.45
+2.20 (0.15%)
Dr. Reddy's Laboratories
₹1374.55
+28.30 (2.10%)
Zydus Lifesciences
₹1141.00
+41.35 (3.76%)
Lupin
₹2476.10
+77.40 (3.23%)
Mankind Pharma
₹2531.15
+43.75 (1.76%)
Aurobindo Pharma
₹1620.10
+60.05 (3.85%)
Laurus Labs
₹1543.70
+18.50 (1.21%)
Top Gainers Today
FAQs on NOVELIX PHARMACEUTICALS LIMITE Share Price
What is NOVELIX PHARMACEUTICALS LIMITE share price today?
NOVELIX PHARMACEUTICALS LIMITE share price is ₹77.97 as on 03 Jul, 2026, 15:24 IST.
How has the NOVELIX PHARMACEUTICALS LIMITE share price performed in the past?
In the last 1 year, NOVELIX PHARMACEUTICALS LIMITE delivered a return of 96.45%. The NOVELIX PHARMACEUTICALS LIMITE share price hit a high of ₹92.00 and low of ₹37.71.
How much is the Mutual Fund shareholding in NOVELIX PHARMACEUTICALS LIMITE shares?
The Mutual Fund Shareholding in NOVELIX PHARMACEUTICALS LIMITE was 0.00% at the end of Jun 2026.
What is the the 52-week high and low of NOVELIX PHARMACEUTICALS LIMITE shares ?
The 52-week high and low of NOVELIX PHARMACEUTICALS LIMITE share is ₹92.00 and ₹37.71 as of 03 Jul, 2026.
What is the market cap of NOVELIX PHARMACEUTICALS LIMITE?
The market capitalisation of NOVELIX PHARMACEUTICALS LIMITE is ₹58.64 Crores as on 03 Jul, 2026.
What are the stock symbols of NOVELIX PHARMACEUTICALS LIMITE?
The stock symbol of NOVELIX PHARMACEUTICALS LIMITE is 536565 on the BSE, and the ISIN is INE314I01036.
What was yesterday's closing price for NOVELIX PHARMACEUTICALS LIMITE shares ?
NOVELIX PHARMACEUTICALS LIMITE shares closed yesterday at ₹78.60 on BSE
How to buy NOVELIX PHARMACEUTICALS LIMITE shares?
To buy NOVELIX PHARMACEUTICALS LIMITE shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy NOVELIX PHARMACEUTICALS LIMITE shares on Holidays?
No, shares of NOVELIX PHARMACEUTICALS LIMITE or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell NOVELIX PHARMACEUTICALS LIMITE shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of NOVELIX PHARMACEUTICALS LIMITE?
The PE and PB ratio of NOVELIX PHARMACEUTICALS LIMITE is -27 and 3.24 respectively, as on 03 Jul, 2026, 15:24 IST.